author_facet Hummel, Michael
Specht, Cornelia
Hummel, Michael
Specht, Cornelia
author Hummel, Michael
Specht, Cornelia
spellingShingle Hummel, Michael
Specht, Cornelia
Journal of Laboratory Medicine
Biobanks for future medicine
Biochemistry (medical)
Clinical Biochemistry
Discrete Mathematics and Combinatorics
author_sort hummel, michael
spelling Hummel, Michael Specht, Cornelia 2567-9449 2567-9430 Walter de Gruyter GmbH Biochemistry (medical) Clinical Biochemistry Discrete Mathematics and Combinatorics http://dx.doi.org/10.1515/labmed-2019-0106 <jats:title>Abstract</jats:title> <jats:p>The use of biospecimens for biomedical research is not a new idea. Many important developments for a better understanding of diseases have been made using patient samples and related data. In former times, this was realized by individual researchers and therefore not under controlled conditions. In early times, patients were not asked for their consent and quality of biosamples and data were assessed applying subjective criteria. This has changed significantly in the past two decades especially in terms of patient consent, ethical approval and data privacy. With respect to quality, it has been extremely difficult to establish clear guidelines due to the great heterogeneity of the downstream applications. Especially in the last decade, the impact and importance of well-defined and well-organized centralized biobank infrastructures was recognized globally and enormous efforts have been undertaken to establish and operate institutional biobanks in many of the medical centers. The most recent development refers to the cooperation of biobanks at different locations. Those biobank networks enable the query for biospecimens and data across biobanks in order to collect sufficient number of samples from small disease subgroups which would not be possible for single sites. To serve this need is of utmost importance as the advances in omics technologies allow a highly sophisticated subdivision of diseases into small molecular subgroups. Moreover, the existence of many disease subgroups, which can be ideally targeted with a tailored treatment, challenges the pharma industry: in order to support the development of personalized treatment options, biobank networks offering well-defined patient samples of high quality and with rich clinical information are becoming essential partners not only in academic research but also for companies developing diagnostic tools or new therapies.</jats:p> Biobanks for future medicine Journal of Laboratory Medicine
doi_str_mv 10.1515/labmed-2019-0106
facet_avail Online
Free
finc_class_facet Medizin
Biologie
Chemie und Pharmazie
Mathematik
Informatik
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9sYWJtZWQtMjAxOS0wMTA2
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9sYWJtZWQtMjAxOS0wMTA2
institution DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Zi4
DE-Gla1
DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
imprint Walter de Gruyter GmbH, 2019
imprint_str_mv Walter de Gruyter GmbH, 2019
issn 2567-9449
2567-9430
issn_str_mv 2567-9449
2567-9430
language Undetermined
mega_collection Walter de Gruyter GmbH (CrossRef)
match_str hummel2019biobanksforfuturemedicine
publishDateSort 2019
publisher Walter de Gruyter GmbH
recordtype ai
record_format ai
series Journal of Laboratory Medicine
source_id 49
title Biobanks for future medicine
title_unstemmed Biobanks for future medicine
title_full Biobanks for future medicine
title_fullStr Biobanks for future medicine
title_full_unstemmed Biobanks for future medicine
title_short Biobanks for future medicine
title_sort biobanks for future medicine
topic Biochemistry (medical)
Clinical Biochemistry
Discrete Mathematics and Combinatorics
url http://dx.doi.org/10.1515/labmed-2019-0106
publishDate 2019
physical 383-388
description <jats:title>Abstract</jats:title> <jats:p>The use of biospecimens for biomedical research is not a new idea. Many important developments for a better understanding of diseases have been made using patient samples and related data. In former times, this was realized by individual researchers and therefore not under controlled conditions. In early times, patients were not asked for their consent and quality of biosamples and data were assessed applying subjective criteria. This has changed significantly in the past two decades especially in terms of patient consent, ethical approval and data privacy. With respect to quality, it has been extremely difficult to establish clear guidelines due to the great heterogeneity of the downstream applications. Especially in the last decade, the impact and importance of well-defined and well-organized centralized biobank infrastructures was recognized globally and enormous efforts have been undertaken to establish and operate institutional biobanks in many of the medical centers. The most recent development refers to the cooperation of biobanks at different locations. Those biobank networks enable the query for biospecimens and data across biobanks in order to collect sufficient number of samples from small disease subgroups which would not be possible for single sites. To serve this need is of utmost importance as the advances in omics technologies allow a highly sophisticated subdivision of diseases into small molecular subgroups. Moreover, the existence of many disease subgroups, which can be ideally targeted with a tailored treatment, challenges the pharma industry: in order to support the development of personalized treatment options, biobank networks offering well-defined patient samples of high quality and with rich clinical information are becoming essential partners not only in academic research but also for companies developing diagnostic tools or new therapies.</jats:p>
container_issue 6
container_start_page 383
container_title Journal of Laboratory Medicine
container_volume 43
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792336381849108487
geogr_code not assigned
last_indexed 2024-03-01T14:59:16.372Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Biobanks+for+future+medicine&rft.date=2019-12-18&genre=article&issn=2567-9430&volume=43&issue=6&spage=383&epage=388&pages=383-388&jtitle=Journal+of+Laboratory+Medicine&atitle=Biobanks+for+future+medicine&aulast=Specht&aufirst=Cornelia&rft_id=info%3Adoi%2F10.1515%2Flabmed-2019-0106&rft.language%5B0%5D=und
SOLR
_version_ 1792336381849108487
author Hummel, Michael, Specht, Cornelia
author_facet Hummel, Michael, Specht, Cornelia, Hummel, Michael, Specht, Cornelia
author_sort hummel, michael
container_issue 6
container_start_page 383
container_title Journal of Laboratory Medicine
container_volume 43
description <jats:title>Abstract</jats:title> <jats:p>The use of biospecimens for biomedical research is not a new idea. Many important developments for a better understanding of diseases have been made using patient samples and related data. In former times, this was realized by individual researchers and therefore not under controlled conditions. In early times, patients were not asked for their consent and quality of biosamples and data were assessed applying subjective criteria. This has changed significantly in the past two decades especially in terms of patient consent, ethical approval and data privacy. With respect to quality, it has been extremely difficult to establish clear guidelines due to the great heterogeneity of the downstream applications. Especially in the last decade, the impact and importance of well-defined and well-organized centralized biobank infrastructures was recognized globally and enormous efforts have been undertaken to establish and operate institutional biobanks in many of the medical centers. The most recent development refers to the cooperation of biobanks at different locations. Those biobank networks enable the query for biospecimens and data across biobanks in order to collect sufficient number of samples from small disease subgroups which would not be possible for single sites. To serve this need is of utmost importance as the advances in omics technologies allow a highly sophisticated subdivision of diseases into small molecular subgroups. Moreover, the existence of many disease subgroups, which can be ideally targeted with a tailored treatment, challenges the pharma industry: in order to support the development of personalized treatment options, biobank networks offering well-defined patient samples of high quality and with rich clinical information are becoming essential partners not only in academic research but also for companies developing diagnostic tools or new therapies.</jats:p>
doi_str_mv 10.1515/labmed-2019-0106
facet_avail Online, Free
finc_class_facet Medizin, Biologie, Chemie und Pharmazie, Mathematik, Informatik
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9sYWJtZWQtMjAxOS0wMTA2
imprint Walter de Gruyter GmbH, 2019
imprint_str_mv Walter de Gruyter GmbH, 2019
institution DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1, DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229
issn 2567-9449, 2567-9430
issn_str_mv 2567-9449, 2567-9430
language Undetermined
last_indexed 2024-03-01T14:59:16.372Z
match_str hummel2019biobanksforfuturemedicine
mega_collection Walter de Gruyter GmbH (CrossRef)
physical 383-388
publishDate 2019
publishDateSort 2019
publisher Walter de Gruyter GmbH
record_format ai
recordtype ai
series Journal of Laboratory Medicine
source_id 49
spelling Hummel, Michael Specht, Cornelia 2567-9449 2567-9430 Walter de Gruyter GmbH Biochemistry (medical) Clinical Biochemistry Discrete Mathematics and Combinatorics http://dx.doi.org/10.1515/labmed-2019-0106 <jats:title>Abstract</jats:title> <jats:p>The use of biospecimens for biomedical research is not a new idea. Many important developments for a better understanding of diseases have been made using patient samples and related data. In former times, this was realized by individual researchers and therefore not under controlled conditions. In early times, patients were not asked for their consent and quality of biosamples and data were assessed applying subjective criteria. This has changed significantly in the past two decades especially in terms of patient consent, ethical approval and data privacy. With respect to quality, it has been extremely difficult to establish clear guidelines due to the great heterogeneity of the downstream applications. Especially in the last decade, the impact and importance of well-defined and well-organized centralized biobank infrastructures was recognized globally and enormous efforts have been undertaken to establish and operate institutional biobanks in many of the medical centers. The most recent development refers to the cooperation of biobanks at different locations. Those biobank networks enable the query for biospecimens and data across biobanks in order to collect sufficient number of samples from small disease subgroups which would not be possible for single sites. To serve this need is of utmost importance as the advances in omics technologies allow a highly sophisticated subdivision of diseases into small molecular subgroups. Moreover, the existence of many disease subgroups, which can be ideally targeted with a tailored treatment, challenges the pharma industry: in order to support the development of personalized treatment options, biobank networks offering well-defined patient samples of high quality and with rich clinical information are becoming essential partners not only in academic research but also for companies developing diagnostic tools or new therapies.</jats:p> Biobanks for future medicine Journal of Laboratory Medicine
spellingShingle Hummel, Michael, Specht, Cornelia, Journal of Laboratory Medicine, Biobanks for future medicine, Biochemistry (medical), Clinical Biochemistry, Discrete Mathematics and Combinatorics
title Biobanks for future medicine
title_full Biobanks for future medicine
title_fullStr Biobanks for future medicine
title_full_unstemmed Biobanks for future medicine
title_short Biobanks for future medicine
title_sort biobanks for future medicine
title_unstemmed Biobanks for future medicine
topic Biochemistry (medical), Clinical Biochemistry, Discrete Mathematics and Combinatorics
url http://dx.doi.org/10.1515/labmed-2019-0106